Anti-diabetic drugs

Antidiabetic Drugs other than Insulin. Table 4 Main exclusions, adverse events and precautionary monitoring required for clinical use of oral anti-diabetic drugs... 

List some nursing diagnoses particular to a patient taking an anti diabetic drug. 

SUMMARY DRUG TABLE ANTI DIABETIC DRUGS... 

Fryer, L. G., Parbu-Patel, A., and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277 25226-25232. 

Now take an essentially sound experimental design. We want to determine the average elimination half-life of a new anti-diabetic drug in type II diabetics aged 50-75, within Western Europe. We recruit several hospitals scattered throughout Western Europe and they draw up a census of all the appropriately aged, type II diabetics under their care. From these lists we then randomly select potential subjects. 

Endocrine effect Insulin, anti-diabetes drugs Monitor blood glucose... 

Ikumi, Y., Kida, T., Sakuma, S., Yamashita, S. and Akashi, M. (2008) Polymer—phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+ /glucose cotransporter (SGLT1) in the small intestine. Journal of Controlled Release, 125 (1), 42—49. 

Left two representatives of two groups of orally applied anti-diabetic drugs. Compound 1 derives from sulfonylurea and 2 from thiazolidinedione. Right schematic drawing of the hormone insulin. The active form, a monomer (shown), consists of two peptide chains which are hnked by two disulfide bridges. Chain A contains an additional disulfide hnk. 

Table 1. Effects of oral anti-diabetic drugs on HbAlc, hypoglycaemic events and weight change in four randomized double-blind studies (QUARTET) results after 1 year.

The anti-diabetic drug phenformin (jS-phenylethylbiguanide) forms chelates with cupric ions with avidity similar to that of glycine. Among related compounds, the ability to chelate copper runs parallel to the anti-diabetic activity which is effected by inhibition of hepatic gluconeogenesis (Foye, O Laughlin and Duvall, 1961). 

Choi, J.H., Banks, A.S., Estall, J.L., et al. (2010) Anti-diabetic drugs inhibit obesity-hnked phosphorylation of PPARy by Cdk5. Nature, 466 (7305), 451-456. 

FDA (2007) FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. Agency says drug to remain on market, while safety assessment continues. Aveiilable at http //www.fda gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucml09026.htm. Accessed 2 Jan 2016... 

---